Phase I Evaluation of Oral and Intravenous Vinorelbine in Pediatric Cancer Patients: A Report from the Children's Oncology Group
- 15 January 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 12 (2), 516-522
- https://doi.org/10.1158/1078-0432.ccr-05-1541
Abstract
Purpose: Vinorelbine (Navelbine) is an orally absorbable Vinca with broad antitumor activity. It differs from other Vinca in that it is structurally modified on the catharanthine nucleus and has differential actions on tubulin that render it less neurotoxic than other compounds in this class. We conducted a phase I study of vinorelbine given the activity of Vinca alkaloids in many pediatric tumors. Experimental Design: We evaluated the safety and pharmacokinetics of oral and i.v. vinorelbine administered weekly × 6 in children (age, 2-17 years) with different tumors. Patients with disease involvement in the bone marrow were eligible but were stratified and dose-escalated separately. Oral vinorelbine (week 1) was administered as liquid-filled gelatin capsules at thrice the i.v. dose. Intravenous vinorelbine doses of 24 to 37.5 mg/m2 were administered on weeks 2 to 6. Results: The dose-limiting toxicity in patients without marrow involvement was reversible neutropenia. Common nonhematologic toxicities included ≤ grade 2 nausea/vomiting and increased hepatic transaminases. A higher mean i.v. ClTB was observed (1.75 ± 1.0 L/h/kg) compared with adult reports, with a mean t1/2B of 16.5 ± 9.7 hours. Mean oral bioavailability was 28.5 ± 22.5%. The apparent oral clearance (12.1 ± 13.0 L/h/kg) and volume of distribution (69.4 ± 30.6 L/kg) were substantially higher than in adults given similar oral doses. Conclusions: The maximum tolerated dose in children without bone marrow involvement was 30 mg/m2, similar to that reported in adults, with myelosuppression being the dose-limiting toxicity. Higher plasma clearance resulted in lower area under the plasma concentration-time curves at a given dose compared with that reported in adults.Keywords
This publication has 12 references indexed in Scilit:
- Gemcitabine plus vinorelbine in stage IIIB or IV non-small cell lung cancer (NSCLC): a multicentre phase II clinical trialLung Cancer, 2001
- Mechanism of Mitotic Block and Inhibition of Cell Proliferation by the Semisynthetic Vinca Alkaloids Vinorelbine and Its Newer Derivative VinfluninePublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2001
- Phase II Trial of Docetaxel and Vinorelbine in Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2000
- Therapeutic efficacy of vinorelbine against pediatric and adult central nervous system tumorsCancer Chemotherapy and Pharmacology, 1998
- The effects of food and divided dosing on the bioavailability of oral vinorelbineCancer Chemotherapy and Pharmacology, 1996
- Pharmacokinetics of vinorelbine in manEuropean Journal of Clinical Pharmacology, 1992
- Oral administration of [3H]navelbine in patientsAnti-Cancer Drugs, 1991
- Pharmacokinetics of navelbine after oral administration in cancer patientsCancer Chemotherapy and Pharmacology, 1991
- Phase I pharmacologic study of a new Vinca alkaloid: NavelbineCancer Letters, 1985
- Oral vinzolidine as therapy for Kaposi's sarcoma and carcinomas of lung, breast, and colon/rectumCancer Chemotherapy and Pharmacology, 1985